Endometriosis Endometriose Epigallocatechin gallate Epigallocatechine gallaat EGCG Green tea Groene thee
Conditions
Interventions
Epigallocatechin gallate capsules 225 mg 3 times a day (total dosage a day of 675 mg) for three months.
Sponsors
VU university medical center
Department of Obstretics and Gynaecology
Eligibility
Inclusion criteria
Inclusion criteria: 1. Signed and dated informed consent; 2. The use of oral contraceptives; 3. Pain associated with visually proven endometriosis determined by diagnostic laparoscopy; 4. Negative pregnancy test; 5. Threshold for pelvic painscore: Minimum of 40 mm on VAS during menstruation at screening; 6. Transvaginal ultrasound within the last 3 months; 7. Good general health (except for endometriosis).
Exclusion criteria
Exclusion criteria: 1. Previous/ current use of hormonal agents including GnRH agonists (not within 6 cycles), progestins (not within 3 cycles), hormonal contraception (not within 1 cycle), IUD (mirena), specific oral contraceptives (Diane 35 and three phase oral contraceptives, not within one cycle); 2. Positive pregnancy test; 3. Breastfeeding; 4. Blood coagulation disorders; 5. Liver dysfunction; 6. Usage of any prescription drug; 7. Contra indication for usage of ibuprofen.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. To evaluate if the VAS pain scores are lower in patients using EGCG versus placebo treatment; 2. To evaluate if serum Ca-125 level is lower in patients using EGCG versus placebo treatment; 3. To investigate if the total dosage of rescue pain medication is lower in patients using EGCG versus placebo treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. To investigate if the Biberoglu & Behrman severity profile is lower in patients using EGCG versus placebo treatment; 2. To investigate if the menstrual bloodloss is lower in patients using EGCG versus placebo treatment. | — |
Contacts
Public ContactP.G.A. Hompes
P.O. Box 7057
Outcome results
None listed